Nafamostat for prophylaxis against post-endoscopic retrograde cholangiopancreatography pancreatitis compared with gabexate

Gut and Liver

Volumn 3, Issue 3, 2009, Pages 205-210

  Jae, Hyuck Chang ^a   In, Seok Lee ^a   Hyung, Keun Kim ^a   Yu, Kyung Cho ^a   Jae, Myung Park ^a   Sang, Woo Kim ^a   Choi, Myung Gyu ^a   Chung, In Sik ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Endoscopic retrograde cholangiopancreatography; Gabexate; Hyperamylasemia; Nafamostat; Pancreatitis

Indexed keywords

AMYLASE; GABEXATE; GABEXATE MESILATE; NAFAMSTAT; NAFAMSTAT MESILATE;

ACUTE PANCREATITIS; ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG POTENCY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HYPERAMYLASEMIA; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PREOPERATIVE TREATMENT; PROPHYLAXIS;

EID: 70349303372     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2009.3.3.205     Document Type: Article

References (23)

1. Manes G, Ardizzone S, Lombardi G, Uomo G, Pieramico O, Porro GB. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 2007;65:982-987. (Pubitemid 46783824)
2. Cheon YK, Cho KB, Watkins JL, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc 2007;66:1126-1132.
3. Zheng M, Chen Y, Yang X, Li J, Zhang Y, Zeng Q. Gabexate in the prophylaxis of post-ERCP pancreatitis: a metaanalysis of randomized controlled trials. BMC Gastroenterol 2007;7:6. (Pubitemid 46351551)
4. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003;124:1786-1791. (Pubitemid 36666775)
5. Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol 2007;102:978-983. (Pubitemid 46698240)
6. Andriulli A, Caruso N, Quitadamo M, et al. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. JOP 2003;4:41-48. (Pubitemid 38963799)
7. Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007;65:624-632. (Pubitemid 46442832)
8. Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP 2002;3:162-168. (Pubitemid 38963805)
9. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004;59:845-864. (Pubitemid 38879313)
10. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981;661:342-345. (Pubitemid 12233442)
11. Iwaki M, Ino Y, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamostat mesilate: V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol 1986;41:155-162.
12. Keck T, Balcom JH, Antoniu BA, et al. Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis. Surgery 2001; 130:175-181. (Pubitemid 32721666)
13. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-393.
14. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography: Gabexate in digestive endoscopy - Italian Group. N Engl J Med 1996;335:919-923.
15. Masci E, Cavallini G, Mariani A, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post- ERCP pancreatitis. Am J Gastroenterol 2003;98:2182-2186. (Pubitemid 37305356)
16. Testoni PA, Mariani A, Masci E, Curioni S. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. Dig Liver Dis 2006;38:588-595. (Pubitemid 44356251)
17. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56:488-495.
18. Andriulli A, Solmi L, Loperfido S, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004;2:713-718. (Pubitemid 39013432)
19. Hartwig W, Jimenez RE, Werner J, et al. Interstitial trypsinogen release and its relevance to the transformation of mild into necrotizing pancreatitis in rats. Gastroenterology 1999;117:717-725. (Pubitemid 29409259)
20. Steer ML. Frank Brooks memorial lecture: the early intraacinar cell events which occur during acute pancreatitis. Pancreas 1998;17:31-37.
21. Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol 2007;46:947-954. (Pubitemid 46546604)
22. Rudin D, Kiss A, Wetz RV, Sottile VM. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol 2007; 22:977-983. (Pubitemid 47019864)
23. Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas 2008;37:445-448.